The Peer-Group Mispricing Sitting On BSX Stock

This medical device maker posts elite numbers but wears a bargain-bin price tag, and the reason is a sudden crisis of confidence in its star products.

Boston Scientific (BSX) stock has been a tough holding, down 56% over the last twelve months and trading near $46.84 a share. Yet inside its competitive group, the company presents a stark contradiction. Consider Medtronic, which trades at 24.3 times earnings on revenue growth of 8.4%. Boston Scientific grew faster than most of its peer set at 13.5%, yet trades for just 18.7 times earnings-well below slower-growing peers like Medtronic and Abbott. While Becton Dickinson commands a group-high 55.3 times earnings on faster 17.4% growth, Boston Scientific's discount against the rest of the group remains pronounced. Does Boston Scientific's top-tier operational performance justify a bottom-tier price tag, or is the market appropriately repricing lower medium-term growth?

Boston Scientific delivers growth and margins its pricier rivals don't.

By the numbers, Boston Scientific's performance puts it near the top of its peer set. Its 13.5% revenue growth over the last twelve months is second only to Becton Dickinson (17.4%) and comfortably outpaces Stryker (8.5%) and Abbott Laboratories (8.1%). Yet both Stryker and Abbott command far richer valuations, trading at 34.0 and 36.1 times earnings, respectively.

The story is similar on profitability. Boston Scientific's operating margin of 21% is solid, ranking third in the group. It runs ahead of Medtronic's 18.8% margin, yet Medtronic carries a higher valuation. In short, the company is delivering the kind of results the market usually pays a premium for, but in this case, it's getting a discount.

So why has the market derated the stock?

The market's skepticism isn't coming from nowhere. Management recently lowered its annual profit forecast, a move driven by sudden and severe weakness in two of its most important growth engines. The company's guidance reduction, according to the CEO, is concentrated in its WATCHMAN heart device and its Electrophysiology (EP) business.

For WATCHMAN, management noted the U.S. market has "slowed sharply and unexpectedly," which they attribute to "compounding clinical evidence, which has impacted referral patterns." In Electrophysiology, the company admitted it "did not anticipate the degree of competitive share movement" it is now seeing. These are not temporary stumbles. Management stated its assumption is that these dynamics will persist through 2027, resulting in "revenue growth below our WAMGR and limited adjusted EPS growth." Growing below its weighted-average market growth rate (WAMGR)-which management sizes at 7% to 8%-means the company expects to lose market share rather than simply miss an internal target.

The test is whether the core business can bridge the gap to 2028.

While the problems in WATCHMAN and EP are serious, they don't tell the whole story. Management is quick to point out that its other businesses, which "represent roughly 75% of our revenue, are expected to grow approximately 6% in the second half of the year." This provides a stable foundation while the company works to fix its trouble spots. The company also announced a restructuring program aimed to deliver "approximately $500 million in run rate savings exiting '29" to improve efficiency.

The bull case hinges on what comes after the slowdown. Management is looking toward a significant re-acceleration in 2028, driven by what it calls "7 new meaningful launches that exceed about a $25 billion TAM in 2028." For investors wondering if they should hold the stock for its next device, this pipeline is the central argument. For those who prefer to invest in the broader healthcare theme, a healthcare ETF like XLV offers exposure to the entire sector.

The immediate question is one of credibility. After cutting its forecast, the first step is to prove it can hit the new, lower targets. The key metric to watch, therefore, is the company's full-year 2026 organic revenue guidance of 5% to 6%. While hitting that target would signal near-term stabilization, it also confirms that the trailing 13.5% growth advantage over peers has vanished, leaving the stock to navigate a period where forward growth lags the very competitors it previously outperformed.

To keep score on this group beyond today, our full peer-by-peer dashboards for BSX track the whole lineup, metric by metric.

Even the best of the group is still one stock

Whichever name wins a peer comparison, buying it concentrates your capital in single-company risk. Even within a single sector, individual winners and losers drift dramatically-making company-specific stumbles difficult to absorb without broader portfolio diversification.

The Trefis High Quality (HQ) Portfolio diversifies across roughly 30 quality names in different industries, selected on fundamentals and re-balanced with discipline, so no single group's weather decides the outcome. It has a track record of outpacing a benchmark that combines the three major indices - the S&P 500, S&P Mid-cap, and Russell 2000. Use the comparison to understand the stock; use the portfolio to own the market's best.